Relevant additions and changes to the 1 April 2014 issue of the Schedule of Pharmaceutical Benefits have been added to MAESTrO Australia

[:content [\1 \space \A \p \r \i \l \space \2 \0 \1 \4 \space \- \space \T \h \e \space \f \o \l \l \o \w \i \n \g \space \a \d \d \i \t \i \o \n \s \space \a \n \d \space \c \h \a \n \g \e \s \space \h \a \v \e \space \b \e \e \n \space \a \d \d \e \d \space \t \o \space \M \A \E \S \T \r \O \space \A \u \s \t \r \a \l \i \a \: " ..."]]
Read more →

Several new features are currently in development and will be added soon

[:content [\T \h \e \s \e \space \f \e \a \t \u \r \e \s \space \i \n \c \l \u \d \e \space \l \i \n \k \s \space \t \o \space \D \U \S \C \space \O \u \t \c \o \m \e \space \S \t \a \t \e \m \e \n \t \s \space \( \2 \0 \1 \2 \- \2 \0 \1 \3 \) \space \a \n \d \space \i \m \p \r \o \v \e \d \space \s \u \m \m \a \r \i \e \s \space \f \o \r \space \P \B \A \C \space \m \e \e \t \i \n \g \s \space \a \n \d \space \a \p \p \l \i \c \a \n \t \s \. \space \T \h \e \space \s \u \m \m \a \r \i \e \s \space \w \i \l \l " ..."]]
Read more →

NHS England to fund hepatitis C drug Sovaldi

[:content [\1 \6 \space \A \p \r \i \l \space \2 \0 \1 \4 \space \- \  \H \e \p \a \t \i \t \i \s \space \C \space \p \a \t \i \e \n \t \s \space \i \n \space \t \h \e \space \U \K \space \a \r \e \space \c \e \l \e \b \r \a \t \i \n \g \space \t \h \e \space \n \e \w \s \space \t \h \a \t \space \N \H \S \space \E \n \g \l \a \n \d \space \h \a \s \space \a \p \p \r \o \v \e \d \space \a \n \space \Â \£ \1 \8 \. \7 " ..."]]
Read more →

Enzalutamide to be reimbursed via PBS for the management of castration-resistant metastatic prostate cancer for men whose disease has progressed on or after docetaxel therapy

Astellas Pharma Australia has announced that Xtandi (enzalutamide) will be listed on the Pharmaceutical Benefits Scheme from 1st December 2014 for the ...

Read more →

New Zealand Pharmaceutical Schedule - March 2014 update

[:content [\1 \space \M \a \r \c \h \space \2 \0 \1 \4 \space \- \space \T \h \e \space \M \a \r \c \h \space \2 \0 \1 \4 \space \u \p \d \a \t \e \space \t \o \space \t \h \e \space \N \e \w \space \Z \e \a \l \a \n \d \space \P \h \a \r \m \a \c \e \u \t \i \c \a \l \space \S \c \h \e \d \u \l \e \space \i \s \space \o \u \t \space \a \n \d \space \n \o \w \i \n \space \e \f \f \e \c \t \. \space \T \h \e " ..."]]
Read more →

Access to Medicines Working Group (AMWG) Communique - 28 October 2014

The communique from the 28 October 2014 AMWG meeting is now available on the PBS website. ...

Read more →

Costly cancer drugs face chop from CDF

Proposed changes to the way the Cancer Drugs Fund is run in England are to go ahead so that, for ...

Read more →

New Zealand Pharmaceutical Schedule - 1 January 2015 update

The January 2015 issue of the New Zealand Pharmaceutical Schedule is out and now in effect. There are no new major ...

Read more →

Health Canada issues notice of compliance for Sovaldi (sofosbuvir) for the treatment of chronic hepatitis C

[:content [\1 \6 \space \D \e \c \e \m \b \e \r \space \2 \0 \1 \3 \space \- \  \G \i \l \e \a \d \space \S \c \i \e \n \c \e \s \  \  \t \o \d \a \y \space \a \n \n \o \u \n \c \e \d \space \t \h \a \t \  \H \e \a \l \t \h \space \C \a \n \a \d \a \  \h \a \s \space \i \s \s \u \e \d \space \a \space \N \o \t \i \c \e \space \o \f \space \C \o \m \p \l \i \a \n \c \e \space \f \o \r \space \S \o \v \a \l \d \i \space \( \s \o \f \o \s \b \u \v \i \r \) \space \4 \0 \0 \space \m \g \space \t \a \b \l \e \t \s \, \space \a " ..."]]
Read more →

NICE says Novartis' Certican costs too much for NHS

The National Institute for Health and Care Excellence is sticking with its stance that Novartis’ Certican is too expensive for ...

Read more →

How NICE can get innovative cancer meds into NHS

The National Institute for Health and Care Excellence is making progress in improving access to new cancer treatments but it ...

Read more →

Hasty cuts may make it harder to access the new medicines that patients need

Health Minister, Sussan Ley’s announcement to list new medicines and vaccines on the PBS for cancer, blindness and shingles will ...

Read more →

PHARMAC notification of delay of decision on proposal to reinstate monthly dispensing on various pharmaceuticals (remove ‘stat’ dispensing)

PHARMAC would like to advise all interested parties that there will be a delay in the decision on a proposal ...

Read more →

Report on the collection of under co-payment data 2013-14

The 2013-14 Report on the Collection of PBS/RPBS Under Co-payment Prescription Data is now available from the PBS website. ...

Read more →

The pCODR program is moving

Effective April 1, 2015, the pCODR office will be moving to a new location in downtown Toronto -just a few ...

Read more →